Last reviewed · How we verify
NCT07172191: HEMAT-FMT
Fecal Microbiota Transplantation Among Adult Patients With Hematological Malignancies
NA trial testing Fecal Microbial Transplantation in Malignant Hematologic Neoplasm in 100 participants. Enrolling by invitation.
31 December 2028
Quick facts
| Lead sponsor | Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 October 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Hungary |
Drugs / interventions tested
- Fecal Microbial Transplantation — full drug profile →
Conditions studied
- Malignant Hematologic Neoplasm — all drugs for Malignant Hematologic Neoplasm →
Sponsor
Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases
Who can join
Eligibility, any sex, with Malignant Hematologic Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In Hungary - in comparison to other member states of the European Union - about 75000 new cases of cancer are diagnosed annually, from which approximately 4500-5000 patients suffer from so-called malignant hematological diseases. This disease group includes various leukemias (blood cancers) and lymphomas (lymph node cancers). Chemotherapy for patients with malignant hematological diseases is particularly difficult to bear, as it affects the entire body, including the "good" gut bacteria living inside, and recovery can take several years. Due to the decrease of the "good" gut bacteria during treatment, patients are more prone to acquiring various difficult-to-treat infections, which can lead to deterioration of quality of life, prolonged hospitalization, and in the worst cases, death. The method outlined in this research plan is called fecal microbiota transplantation, during which stool from a healthy person is introduced into the body of the sick patient. The "good" gut bacteria present in the stool then restore the patient's entire gut flora (the process is somewhat similar to the use of probiotics available on the market, but it is a much more effective method). This research aims to assess the success of fecal microbiota transplantation in adults with malignant hematological diseases over a long-term follow-up period, thus contributing to the restoration of their acceptable quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07172191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fecal Microbial Transplantation
Trials testing the same drug.
- NCT07509346 — Fecal Microbiota Transplant vs Standard Treatment for Recurrent Non-Obstructive Cholangitis · Phase 2 · not yet recruiting
- NCT06890650 — A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagno · NA · recruiting
- NCT06895252 — A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagno · NA · recruiting
- NCT06890637 — A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Diseas · NA · recruiting
- NCT06906445 — A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Ulcerative C · NA · recruiting
Other Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases trials
Trials by the same sponsor.
- NCT05882331 — Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07172191 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07172191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing